Cyclophosphamide (CY) followed by granulocyte colony-stimulating factor (G-CSF) and G-CSF alone are the most commonly used PBPC mobilization schedules. To investigate whether the use of different mobilization regimens could result in functional differences of CD34+ cells, we analyzed nucleated cells (NC), CD34+ cells, colonyforming cells (CFC) and long-term culture initiating-cells (LTC-IC) in 52 leukaphcrcses from 26 patients with lymphoid malignances, mobilized either by CY+G-CSF (n=16) or G-CSF alone (n=10). Thirtyfour aphérèses from the CY+G-CSF group and 18 aphérèses from the G-CSF group were investigated. The mean (±SEM) number of NC was significantly lower in the CY+G-CSF products than in the G-CSF products (1.24±0.17xlO' vs 3.2±0.54xl(T, P<.0001). The mean (± SEM) incidence of CD34+ cells was significantly higher in the CY+GCSF products than in the G-CSF products (2.9±0.6 % vs 0.9±0.2%, P<.0018). However, the mean (± SEM) numbers of CD34+ cells mobilized per apheresis by CY+G-CSF and G-CSF were not significantly different (2.76±0.6x 10'vs 2.53±0.4xlO', PS .7). Similarly, no significant difference was detected by comparing the numbers (mean ± SEM) of CFC collected with the CY+G-CSF and the G-CSF schedule (10±2xl07 vs 4.6±lxl07, PS .09). Interestingly, CY+G-CSF mobilized CD34+ cells had a significantly higher plating efficiency (mean ± SEM) than G-CSF mobilized CD34+ cells (25.5±2.9% vs 10.8±1.9%, PS .0006). The mean (± SEM) number of LTC-IC was significantly higher in the CY+G-CSF products than in the G-CSF products (6.3±lxl06 vs 3.3±0.3xl06, P<.05). No other factor than the mobilizing regimen was found to significantly influence the yield of collected LTC-IC. In conclusion, our data show that CD34 cells mobilized by CY+G-CSF have higher clonogenic activity and primitive progenitor cell content than CD34+ cells mobilized by G-CSF. As mobilized PBPC containing large number of progenitors lead to safer transplantation, this issue may have implications in autografting.
|Number of pages||1|
|Publication status||Published - 1997|
ASJC Scopus subject areas
- Cancer Research
- Cell Biology